ImmunityBio Inc [NASDAQ: IBRX] surged by $0.07 during the normal trading session on while it closed the day at $2.64.
ImmunityBio Inc stock has also loss -4.35% of its value over the past 7 days. However, IBRX stock has declined by -10.81% in the 3 months of the year. Over the past six months meanwhile, it has lost -5.04% and lost -58.23% year-on date.
The market cap for IBRX stock reached $2.33 billion, with 853.39 million shares outstanding and 91.82 million shares in the current float. Compared to the average trading volume of 9.30M shares, IBRX reached a trading volume of 6746092 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $11.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 20, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 06, 2025, representing the official price target for ImmunityBio Inc stock. Previously, the target price had yet another raise to $6, while BTIG Research analysts kept a Buy rating on IBRX stock. On May 12, 2023, analysts decreased their price target for IBRX shares from 10 to 4.
IBRX stock trade performance evaluation
ImmunityBio Inc [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.35. With this latest performance, IBRX shares dropped by -1.12% in over the last four-week period, additionally sinking by -5.04% over the last 6 months – not to mention a rise of 3.13% in the past year of trading.
ImmunityBio Inc [IBRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ImmunityBio Inc [IBRX] shares currently have an operating margin of -1003.83% and a Gross Margin at 45.92%. ImmunityBio Inc’s Net Margin is presently recorded at -1310.30%.
Return on Equity for this stock declined to -116.15%, with Return on Assets sitting at -116.15%.
ImmunityBio Inc [IBRX]: Institutional Ownership
The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0135%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1448%.
